VolitionRx Limited (VNRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

VolitionRx Limited (VNRX) Healthcare & Pipeline Overview

VolitionRx Limited is an epigenetics company developing a suite of Nu.Q blood tests for global cancer and disease diagnostics, leveraging its proprietary Nucleosomics technology platform. With a gross margin of 89.7%, the company focuses on advancing its innovative diagnostic solutions across human and veterinary health sectors.

What Is the Investment Thesis for VNRX?

VolitionRx Limited presents an investment thesis centered on its pioneering role in epigenetics-based diagnostics, specifically through its Nucleosomics technology platform and Nu.Q product suite. The company's focus on non-invasive blood tests for cancer and disease detection addresses a significant unmet medical need, offering potential for early diagnosis and improved patient outcomes. The robust gross margin of 89.7% indicates strong underlying unit economics for its products, suggesting efficiency in its core operations once commercial scale is achieved. Key growth catalysts include the ongoing development and potential regulatory approvals of its Nu.Q tests for various human and veterinary applications, which could unlock substantial market opportunities in the global diagnostics market. The expansion of its product portfolio, including Nu.Q Nets for immune monitoring and Nu.Q Capture for enhanced sample analysis, diversifies its revenue streams and strengthens its technological moat. However, investors must consider the current financial profile, characterized by a significant negative profit margin of -997.5% and a market capitalization of $9.43M, indicating that the company is in an early commercialization or heavy R&D phase, requiring substantial future capital or revenue growth to achieve profitability. The Beta of 1.03 suggests market-like volatility.

Based on FMP financials and quantitative analysis

VNRX Key Highlights

• VolitionRx Limited maintains a robust Gross Margin of 89.7%, indicating strong cost control relative to its revenue generation from diagnostic products.
• The company operates with a Market Capitalization of $9.43M, reflecting its current valuation within the medical diagnostics and research sector.
• VolitionRx Limited reported a Profit Margin of -997.5%, highlighting its current stage of significant investment in research, development, and commercialization efforts.
• The stock exhibits a Beta of 1.03, suggesting its price movements generally align with the broader market's volatility.
• The company employs a team of 85 individuals, dedicated to advancing its epigenetics-based diagnostic technologies and expanding its product portfolio.

Who Are VNRX's Competitors?

VNRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VNRX's Key Strengths?

• Proprietary Nucleosomics technology platform for epigenetics-based diagnostics.
• Diverse Nu.Q product portfolio targeting human cancer, immune monitoring, and veterinary applications.
• High Gross Margin of 89.7% indicates efficient core operations.
• Focus on non-invasive blood tests addresses a significant market demand for early detection.

What Are VNRX's Weaknesses?

• Significant negative Profit Margin of -997.5% indicates unprofitability and high operational costs.
• Small market capitalization of $9.43M suggests early stage or limited market presence.
• Reliance on ongoing research and development for product pipeline expansion.
• Potential for high capital requirements to fund clinical trials and commercialization.

What Could Drive VNRX Stock Higher?

• Successful completion of clinical trials for new Nu.Q diagnostic applications, demonstrating efficacy and safety for specific cancer types or diseases.
• Receipt of key regulatory approvals (e.g., FDA, CE Mark) for additional Nu.Q tests, enabling broader market access and commercialization efforts.
• Expansion of commercialization partnerships and distribution channels for the Nu.Q product suite in new international markets.
• Continued advancements in the Nucleosomics technology platform, leading to enhanced test performance or new diagnostic capabilities.
• Publication of significant research findings in peer-reviewed journals, validating the utility and accuracy of VolitionRx's epigenetic markers.

What Are the Key Risks for VNRX?

• Financial-distress signal — its Altman Z-Score of -49.00 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant negative profit margin (-997.5%) indicating substantial cash burn and potential need for future financing, which could dilute existing shareholder value.
• Failure to obtain necessary regulatory approvals for its diagnostic tests in a timely manner, delaying commercialization and revenue generation.
• Intense competition from other diagnostic companies, including those developing liquid biopsy and molecular diagnostic solutions, potentially limiting market share.
• Dependence on the successful market adoption and reimbursement for its Nu.Q products, which may be influenced by clinical utility and cost-effectiveness data.
• Rapid technological advancements by competitors or shifts in diagnostic paradigms could render VolitionRx's technology less competitive.

What Are the Growth Opportunities for VNRX?

• Growth opportunity 1: Expansion of Nu.Q Cancer Diagnostics. VolitionRx's primary Nu.Q cancer detection tests represent a significant growth opportunity by addressing the global demand for early, non-invasive cancer screening. The market for cancer diagnostics is substantial, with projections indicating continued expansion due to increasing cancer prevalence and advancements in diagnostic technologies. By securing additional regulatory approvals and expanding commercialization efforts across different geographical regions and cancer types, VolitionRx can capture a larger share of this market. The company's focus on blood-based tests offers a less invasive alternative to traditional biopsies, potentially increasing patient compliance and screening rates, which could drive significant revenue growth over the next five to ten years as adoption increases.
• Growth opportunity 2: Development and Commercialization of Nu.Q Nets. The Nu.Q Nets product line, designed for monitoring the immune system, presents an opportunity to diversify VolitionRx's market reach beyond oncology. Immune system monitoring is crucial in various medical fields, including infectious diseases, autoimmune disorders, and sepsis management. The global market for immune monitoring is growing, driven by the need for personalized treatment strategies and early detection of immune dysregulation. By further developing and commercializing Nu.Q Nets, VolitionRx can tap into these adjacent markets, offering valuable diagnostic insights that complement its cancer detection portfolio. This expansion could provide new revenue streams within the next three to seven years, leveraging its core Nucleosomics platform.
• Growth opportunity 3: Growth in Veterinary Diagnostics with Nu.Q Vet. The Nu.Q Vet cancer screening test for veterinary applications offers a unique growth avenue. The pet care industry, particularly veterinary services and diagnostics, has seen consistent growth, driven by increasing pet ownership and owners' willingness to invest in their pets' health. Early cancer detection in animals can significantly improve outcomes and quality of life. By establishing Nu.Q Vet as a standard screening tool in veterinary practices, VolitionRx can capitalize on this specialized, yet growing, market segment. This strategic diversification allows the company to leverage its core technology in a less stringently regulated environment, potentially accelerating market penetration and revenue generation within the next two to five years.
• Growth opportunity 4: Leveraging Nu.Q Capture for Enhanced Diagnostics. Nu.Q Capture, designed for capturing and concentrating samples, represents a critical enabler for more accurate diagnoses across all of VolitionRx's product lines. As diagnostic sensitivity and specificity are paramount in clinical settings, improving sample quality directly enhances the performance of downstream tests. This product can be marketed both as an integral component of VolitionRx's own testing workflows and as a standalone solution for other diagnostic laboratories. The market for sample preparation technologies is integral to the broader diagnostics market. By demonstrating the value of Nu.Q Capture in improving diagnostic accuracy, VolitionRx can drive adoption, potentially increasing the utility and market acceptance of its entire Nu.Q portfolio over the next three to five years.
• Growth opportunity 5: Advancing Research with Nu.Q Discover. Nu.Q Discover, a solution for profiling nucleosomes, targets the research and development market. This product supports academic institutions, pharmaceutical companies, and biotech firms in their epigenetic research endeavors. The global epigenetics market for research tools is expanding as scientists increasingly recognize the role of epigenetics in disease pathogenesis and drug development. By providing a robust platform for nucleosome profiling, VolitionRx can become a key supplier for researchers, fostering collaborations and potentially leading to new diagnostic or therapeutic discoveries that could license or partner with the company. This opportunity focuses on foundational research, with potential long-term commercialization benefits over a five to ten-year horizon.

What Opportunities Does VNRX Have?

• Expansion into new geographic markets and additional cancer types for Nu.Q tests.
• Growth in the global epigenetics and liquid biopsy diagnostic markets.
• Diversification into immune system monitoring and veterinary diagnostics.
• Strategic partnerships or collaborations to accelerate product development and market penetration.

What Threats Does VNRX Face?

• Intense competition from established diagnostic companies and emerging biotech firms.
• Stringent and lengthy regulatory approval processes for diagnostic tests.
• Risk of technological obsolescence or superior competing diagnostic methods.
• Dependence on successful commercialization and market adoption of its Nu.Q product suite.

What Are VNRX's Competitive Advantages?

• Proprietary Nucleosomics technology platform, which forms the basis for its unique diagnostic approach.
• Specialized Nu.Q product suite targeting specific diagnostic applications in oncology and immunology.
• Expertise in epigenetics, a complex and rapidly evolving field, providing a knowledge barrier to entry.
• Potential for intellectual property protection around its diagnostic methods and markers.

What Does VNRX Do?

VolitionRx Limited is a multi-national epigenetics company headquartered in Henderson, US, with operations also noted in Austin, Texas. Established to address the critical need for early and accurate disease detection, the company specializes in the development and commercialization of innovative blood tests designed to help diagnose a wide range of cancers and other diseases worldwide. At the core of VolitionRx's offerings is its proprietary Nucleosomics technology platform, which forms the foundation for its diverse product portfolio. This platform enables the detection and analysis of nucleosomes, which are fundamental units of DNA packaging that can carry epigenetic information indicative of disease states. The company's product lineup includes several specialized Nu.Q tests. Nu.Q tests are designed for general cancer detection, providing a non-invasive screening tool. Nu.Q Nets are developed for monitoring the immune system, offering insights into inflammatory and infectious conditions. For the veterinary market, VolitionRx offers Nu.Q Vet, a cancer screening test tailored for animal applications, expanding its diagnostic reach beyond human health. Furthermore, the company provides Nu.Q Capture, a solution aimed at capturing and concentrating samples to facilitate more accurate diagnoses, enhancing the utility of its other tests. Lastly, Nu.Q Discover serves as a comprehensive solution for profiling nucleosomes, supporting research and development efforts in epigenetics. With a dedicated team of 85 employees, VolitionRx Limited is positioned within the medical diagnostics and research industry, striving to innovate in the field of epigenetics for improved global health outcomes.

What Products and Services Does VNRX Offer?

• Develops blood tests for diagnosing a range of cancers and other diseases worldwide.
• Sells Nu.Q tests specifically designed for cancer detection.
• Offers Nu.Q Nets for monitoring the human immune system.
• Provides Nu.Q Vet, a cancer screening test tailored for veterinary applications.
• Markets Nu.Q Capture, a solution for enhancing diagnostic accuracy by concentrating samples.
• Supplies Nu.Q Discover, a tool for profiling nucleosomes, primarily for research purposes.
• Operates the Nucleosomics technology platform, which is the foundation for its blood tests.
• Focuses on epigenetics, the study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence.

How Does VNRX Make Money?

• Develops and commercializes proprietary epigenetics-based diagnostic tests for human and veterinary health.
• Generates revenue from the sale of its Nu.Q product line, including tests for cancer detection, immune monitoring, and research tools.
• Leverages its Nucleosomics technology platform for ongoing research, development, and product innovation.
• Aims to secure regulatory approvals for its diagnostic tests to expand market access and adoption globally.

What Industry Does VNRX Operate In?

VolitionRx Limited operates within the dynamic and rapidly evolving Medical - Diagnostics & Research industry, specifically targeting the epigenetics segment. This sector is experiencing significant growth driven by increasing demand for early disease detection, personalized medicine, and non-invasive diagnostic tools. The global market for cancer diagnostics, a primary focus for VolitionRx, is projected to reach substantial valuations, fueled by an aging population and rising cancer incidence rates. VolitionRx's Nucleosomics technology positions it within the competitive landscape of liquid biopsy and molecular diagnostics companies. While the market is characterized by established players and emerging innovators, VolitionRx differentiates itself through its focus on nucleosome-based epigenetic markers. The industry trend towards less invasive and more accurate diagnostic methods provides a fertile ground for the company's Nu.Q product suite, though it must navigate stringent regulatory pathways and intense competition from various diagnostic technologies.

Who Are VNRX's Key Customers?

• Healthcare providers and clinical laboratories seeking non-invasive cancer and disease diagnostic solutions.
• Veterinary clinics and animal hospitals requiring cancer screening tests for pets.
• Research institutions and pharmaceutical companies utilizing nucleosome profiling tools for epigenetic studies.
• Patients benefiting from early and accurate disease detection through blood-based tests.

FY2026 estForward Outlook

Wall Street analysts project VolitionRx Limited revenue of about $2.2M for fiscal 2026, with EPS near $-2.24. The estimate reflects 4 contributing analysts.

F-Score 2/9Financial Health

VolitionRx Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -49.00 places it in the distress zone, a signal of elevated financial risk.

ROE 74%Key Financial Metrics

Return on equity for VolitionRx Limited stands at 74.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.33 means current liabilities exceed short-term assets, a liquidity point worth watching.

VolitionRx Limited (VNRX) Valuation Context

Valued at $9.43M, VNRX is classified as a micro-cap stock. Relative to its peer group, VNRX's quantitative score of 18/100 is below the peer average of 55/100.

Company Profile

VolitionRx Limited operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Cameron Reynolds. VNRX has traded publicly since 2012.

VNRX Financials

VNRX Latest News

VNRX Analyst Consensus

VNRX MoonshotScore

VNRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources